LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

78.61 -3.65

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.5

Max

81.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	147B 147B
Pardavimai	46M 203M
Pelno marža	72,197.866
Darbuotojai	1,069
EBITDA	4.7B 4.6B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+16.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-428M 13B
Ankstesnė atidarymo kaina	82.26
Ankstesnė uždarymo kaina	78.61

Naujienos nuotaikos

By Acuity

58%

42%

295 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-03 18:43; UTC

Svarbiausios naujienos

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026-03-03 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026-03-03 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026-03-03 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-03 22:38; UTC

Svarbiausios naujienos

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026-03-03 22:16; UTC

Uždarbis

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026-03-03 22:09; UTC

Uždarbis

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026-03-03 22:06; UTC

Uždarbis

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026-03-03 22:05; UTC

Uždarbis

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026-03-03 22:03; UTC

Uždarbis

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Tech, Media & Telecom Roundup: Market Talk

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-03 21:45; UTC

Svarbiausios naujienos

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026-03-03 21:37; UTC

Uždarbis

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026-03-03 21:26; UTC

Svarbiausios naujienos

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026-03-03 20:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026-03-03 20:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026-03-03 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold and Silver Drop as Energy Surges -- Market Talk

2026-03-03 18:43; UTC

Uždarbis

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026-03-03 18:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026-03-03 18:14; UTC

Uždarbis

How Long Can Anthropic Play Defense? -- WSJ

2026-03-03 17:41; UTC

Svarbiausios naujienos

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026-03-03 17:36; UTC

Svarbiausios naujienos

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026-03-03 17:28; UTC

Įsigijimai, susijungimai, perėmimai

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

16.96% į viršų

12 mėnesių prognozė

Vidutinis 95.86 USD 16.96%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

295 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.